/PRNewswire/ Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter.
Share this article
Share this article
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ Nevakar Inc. ( Nevakar ), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care, acute pain management, long acting injectables and hospital infections. At inception Nevakar Injectables will operate as a wholly owned subsidiary of Nevakar Inc.
Nevakar Injectables launches with 13 active programs, three of which have been filed with FDA under the 505(b)(2) regulatory pathway. The Company s first NDA was approved by the FDA in October 2020. Five of Nevakar Injectables critical care products were out-licensed to Endo Pharmaceuticals for commercialization in the US and Canada. NovaQuest and H.I.G. have provided financial backing to the company through royalty monetization agreements.